Buckingham Asset Management LLC Acquires 341 Shares of Amgen Inc. (AMGN)
Buckingham Asset Management LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,941 shares of the medical research company’s stock after buying an additional 341 shares during the period. Buckingham Asset Management LLC’s holdings in Amgen were worth $1,303,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the stock. Bank of New York Mellon Corp raised its position in Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock worth $1,403,676,000 after buying an additional 195,200 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after buying an additional 81,362 shares in the last quarter. Swiss National Bank raised its position in Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares in the last quarter. Ameriprise Financial Inc. raised its position in Amgen by 0.7% in the first quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock worth $242,555,000 after buying an additional 10,109 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Amgen by 1.4% in the first quarter. Rhumbline Advisers now owns 1,314,521 shares of the medical research company’s stock worth $215,673,000 after buying an additional 18,213 shares in the last quarter. 78.12% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (AMGN) traded up 1.46% during mid-day trading on Thursday, reaching $176.18. The company’s stock had a trading volume of 1,009,917 shares. The company has a 50-day moving average of $173.53 and a 200-day moving average of $168.31. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The firm has a market cap of $128.55 billion, a PE ratio of 16.05 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the prior year, the business earned $2.84 EPS. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.65%. The ex-dividend date is Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.
WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/buckingham-asset-management-llc-acquires-341-shares-of-amgen-inc-amgn/1534344.html.
AMGN has been the topic of a number of recent analyst reports. Mizuho set a $195.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, May 6th. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, May 9th. Vetr raised shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $179.72 price target on the stock in a research report on Thursday, May 11th. Jefferies Group LLC reissued a “hold” rating and issued a $180.00 price target on shares of Amgen in a research report on Monday, May 22nd. Finally, UBS AG restated a “neutral” rating and issued a $174.00 price objective (down previously from $175.00) on shares of Amgen in a research note on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $186.04.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.